CLNN Clene Inc.

BULLISH Impact: 8/10 8-K
Horizon days Filed May 4, 2026 Processed 1mo ago SEC 0001437749-26-014542
8-K context-dependent: Items 7.01, 8.01
Latest settled — T+20d
CLNN ▼ -24.47% at T+20d
LONG call ✗ call lost -24.47% · α vs SPY -30.12% · entry $8.09 → $6.11
Next anchor: T+60d in 6w
Last close $5.84 (close Jun 12) · -27.81% from $8.09 entry
Entry anchored
May 1, 03:59 PM ET
via Databento tick
T+1d
-18.66%
call -18.66% · α -19.46%
$6.58
settled 6w ago
T+5d
-19.65%
call -19.65% · α -22.59%
$6.50
settled 5w ago
T+20d
-24.47%
call -24.47% · α -30.12%
$6.11
settled 13d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Clene Inc. announces FDA agreement that its CNM-Au8 data may support accelerated approval NDA for ALS, with submission planned for Q3 2026. This is a major regulatory milestone for a $72M market cap biotech.

Actionable Insight

Expect strong price reaction on this regulatory catalyst. Monitor for NDA submission details and any financing announcements given $72M market cap. Prior insider selling may be less relevant post-news.

Key Facts

  • FDA stated proposed data may be capable of supporting accelerated approval NDA for CNM-Au8 in ALS
  • FDA acknowledged NfL could serve as reasonably likely surrogate endpoint
  • NDA submission planned for Q3 2026
  • Phase 3 confirmatory study expected to commence Q1 2027
  • CNM-Au8 has Orphan Drug Designation for ALS
  • Data from Phase 2 HEALEY ALS Platform Trial, RESCUE-ALS, and NIH Expanded Access Protocol support submission

Financial Impact

Potential FDA approval could unlock significant value; no financial data in filing

Risk Factors

  • FDA may not accept NDA or require additional data
  • Accelerated approval not guaranteed; confirmatory trial needed for full approval
  • Company likely needs additional capital to fund operations and trials, potential dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-014542
Exhibit: ex_955500.htm0001437749-26-014542
Document: 0001437749-26-014542-index-headers.html0001437749-26-014542
Document: 0001437749-26-014542-index.html0001437749-26-014542
Document: 0001437749-26-014542.txt0001437749-26-014542
8 reports for CLNN
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+20▲ +19.55%May 5, 2026
Filters
Rows
Reports for CLNN — sortable, filterable
Type Now
May 14, 2026
4w ago
8-K
MIXED ★ 6/10
$7.05 $6.81▼ −3.40%▼ −2.69%$5.84 (−17.16%)
May 14, 2026
4w ago
Press Release
BEARISH ★ 6/10
$7.05 $6.81▲ +3.40%▲ +2.69%$5.84 (+17.16%)
May 5, 2026
5w ago
424B5
BEARISH ★ 7/10
$7.16 $6.50▲ +9.22%▲ +10.35%$5.84 (+18.44%)
May 4, 2026
5w ago
8-K
BULLISH ★ 8/10
$8.09 $6.50▼ −19.65%▼ −22.59%$5.84 (−27.81%)
Apr 10, 2026
9w ago
DEFA14A
NEUTRAL ★ 3/10
$6.48 $6.15▼ −5.09%▼ −8.39%$5.84 (−9.88%)
Mar 17, 2026
12w ago
8-K
BULLISH ★ 7/10
$6.13 $5.73▼ −6.53%▼ −3.87%$5.84 (−4.73%)
Mar 12, 2026
13w ago
8-K
BULLISH ★ 8/10
$5.92 $5.87▼ −0.84%▲ +0.13%$5.84 (−1.35%)
Mar 12, 2026
13w ago
Press Release
MIXED ★ 7/10
$5.92 $5.87▼ −0.84%▲ +0.13%$5.84 (−1.35%)
Showing 8 of 8

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access